CNTO 148
- CAS No.
- 476181-74-5
- Chemical Name:
- CNTO 148
- Synonyms
- Simponi;CNTO 148;Golimumab;Research Grade Golimumab;MK-8259|||SCH 900259|||CNTO-148;Research Grade Golimumab (DHB94404)
- CBNumber:
- CB32657887
- Molecular Formula:
- Molecular Weight:
- 0
- MOL File:
- Mol file
- Modify Date:
- 2024/7/2 8:55:06
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|---|---|
| Signal word | Danger |
| Hazard statements | H334 |
| Precautionary statements | P261-P285-P304+P341-P342+P311-P501 |
CNTO 148 Chemical Properties,Uses,Production
Description
The proinflammatory cytokine tumor necrosis factor-alpha (TNF-α) has been implicated as the primary mediator of articular inflammation in diseases such as RA, PsA, and AS. Targeting TNF-a has been a successful strategy in the intervention of a range of immunoinflammatory disorders. Biologics have risen to the forefront of TNF-α blockade with infliximab, a chimeric monoclonal antibody (mAb), and etanercept, a fusion protein comprised of the ligand-binding segment of the soluble TNF receptor, reaching the market in the late 1990s for the initial indication of RA. Since then, their use has expanded to other diseases of inflammatory etiology, and two additional TNF-α inhibitors have joined the competition. Golimumab, a human anti-TNF-α mAb that binds to both soluble and transmembrane forms of TNF-a, is the first once-monthly subcutaneous agent to enter the market and is currently approved for the treatment of RA in combination with methotrexate (MTX), PsA alone or in combination with MTX, and AS. .
Uses
Treatment of allergic asthma.
Side effects
The most common adverse reactions, occurring with an incidence >5%, were upper respiratory tract infection and nasopharyngitis. Regarding drug interactions, live vaccines should not be administered while being treated with golimumab. As an increased risk of serious infection has been associated with concomitant use of abatacept and anakinra, combination of these drugs is not recommended. Also, golimumab treatment should not be initiated in patients with an active infection. Furthermore, patients should be warned about the higher incidence of malignancies observed with anti-TNF-a therapy and increased risks of worsening or new onset of heart failure, of exacerbation or new onset of demyelinating disease, and of hepatitis B reactivation.
CNTO 148 Preparation Products And Raw materials
Raw materials
Preparation Products
CNTO 148 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | China | 10022 | 58 | Inquiry |
| Hubei Kele Fine Chemical Co., Ltd | 027-59101668 19945030958 | China | 7973 | 58 | Inquiry |
| Wuhan Yingnuo Pharmaceutical Technology Co., Ltd. | +86-027-59232304 15387063101 | China | 9918 | 58 | Inquiry |
| ShangHai Biochempartner Co.,Ltd | 17754423994 17754423994 | China | 8010 | 62 | Inquiry |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | China | 9707 | 58 | Inquiry |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 13720134139 | China | 5370 | 58 | Inquiry |
| Shanghai?Medlife?Pharm-Tech?Co.,?Ltd | 021-59167510 18117107507 | China | 5014 | 58 | Inquiry |
| Shaanxi DIDU pharmaceutical and Chemical Co., Ltd | 17691182729 18161915376 | China | 10011 | 58 | Inquiry |
| Changsha Fuzhen Biotechnology Co.，LTD | 0731-13823398 13823398779 | China | 3104 | 58 | Inquiry |
| Shanghai jerryxing Biomedical Technology Co., Ltd | 17721492509 | China | 5347 | 58 | Inquiry |